An update from Psyence Biomedical ( (PBM) ) is now available.
On April 16, 2025, Psyence Biomedical Ltd. held a Special Meeting of Shareholders, where a proposal for a reverse stock split at a ratio of up to 50-for-1 was approved by 95.78% of the votes cast. This move aims to address compliance issues with Nasdaq’s minimum bid price rule, as the company received a delisting notice due to its stock price falling below $1.00 for 30 consecutive days. Psyence plans to appeal this determination and request a hearing to prevent delisting, which could significantly impact its market presence and investor relations.
More about Psyence Biomedical
Psyence Biomedical Ltd. operates in the biomedical industry, focusing on the development of psychedelic compounds and nutraceutical products. The company is based in Toronto, Ontario, and is involved in research and development activities related to psilocybin and its analogues, although these products have not yet been evaluated or approved by regulatory authorities.
YTD Price Performance: -78.89%
Average Trading Volume: 280,920
Technical Sentiment Signal: Buy
Current Market Cap: $1.99M
Find detailed analytics on PBM stock on TipRanks’ Stock Analysis page.